Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Bruzzi

Showing results (101-110 of 155) with videos related to

Pageof 16
Sort By:
Cancer|August 12, 2004
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trialPier Franco Conte, Valentina Guarneri, Paolo Bruzzi, et al.
Journal of the American College of Cardiology|October 10, 2015
Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal HypertrophyPaolo Ferrazzi, Paolo Spirito, Attilio Iacovoni, et al.
European Journal of Endocrinology|January 21, 2015
Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrenceStephan Petersenn, Albert Beckers, Diego Ferone, et al.
Oncotarget|January 22, 2017
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational studyClaudia Bighin, Beatrice Dozin, Francesca Poggio, et al.
Breast Cancer Research and Treatment|March 23, 2020
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trialAlessandra Gennari, Flavia Foca, Rita Zamarchi, et al.
The Oncologist|August 14, 2013
Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility studyMatteo Clavarezza, Roberto Bordonaro, Bruno Daniele, et al.
International Journal of Cancer|March 5, 2004
Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomasViviana Gismondi, Maurizio Meta, Luigina Bonelli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Comparison Between <sup>18</sup>F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with NivolumabGiovanni Rossi, Matteo Bauckneht, Carlo Genova, et al.
Journal of the National Cancer Institute|September 17, 2011
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trialDavide Bedognetti, Mario Roberto Sertoli, Paolo Pronzato, et al.
Oncotarget|March 20, 2018
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenibPaola Queirolo, Francesco Spagnolo, Virginia Picasso, et al.
Pageof 16

Showing results (101-110 of 155) with videos related to

Sort By:
Pageof 16
Cancer|August 12, 2004
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trialPier Franco Conte, Valentina Guarneri, Paolo Bruzzi, et al.
Journal of the American College of Cardiology|October 10, 2015
Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal HypertrophyPaolo Ferrazzi, Paolo Spirito, Attilio Iacovoni, et al.
European Journal of Endocrinology|January 21, 2015
Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrenceStephan Petersenn, Albert Beckers, Diego Ferone, et al.
Oncotarget|January 22, 2017
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational studyClaudia Bighin, Beatrice Dozin, Francesca Poggio, et al.
Breast Cancer Research and Treatment|March 23, 2020
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trialAlessandra Gennari, Flavia Foca, Rita Zamarchi, et al.
The Oncologist|August 14, 2013
Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility studyMatteo Clavarezza, Roberto Bordonaro, Bruno Daniele, et al.
International Journal of Cancer|March 5, 2004
Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomasViviana Gismondi, Maurizio Meta, Luigina Bonelli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Comparison Between <sup>18</sup>F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with NivolumabGiovanni Rossi, Matteo Bauckneht, Carlo Genova, et al.
Journal of the National Cancer Institute|September 17, 2011
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trialDavide Bedognetti, Mario Roberto Sertoli, Paolo Pronzato, et al.
Oncotarget|March 20, 2018
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenibPaola Queirolo, Francesco Spagnolo, Virginia Picasso, et al.
Pageof 16